Ondansetron 8mg Tablet PCD Company in Maharashtra

Ondansetron 8mg Tablet Franchise Supplier in Gujarat

Ondansetron 8mg Tablet Manufacturer in Tamil Nadu

Best PCD Pharma for Ondansetron 8mg Tablet in Madhya Pradesh

Ondansetron 8mg Tablet Third Party Manufacturer in Haryana
Ondansetron 8mg Tablet Exporter from India

Home/Products /lapatinib-250-mg-tablet

Ondotyle 8 MD Tablet

Composition : Ondansetron (8 mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹95.13/-

Contact For Business Query

LAPANIB 250 Tablet (Lapatinib 250 mg) is a highly specialized, oral, targeted cancer medicine classified as a Dual Tyrosine Kinase Inhibitor (TKI). It is a critical treatment component for patients diagnosed with HER2-positive advanced or metastatic breast cancer.

Mechanism and Impact:Lapatinib works by selectively and reversibly binding to the intracellular domain of two key receptors: Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor (EGFR). By competitively blocking the signaling pathways, Lapatinib effectively halts the uncontrolled tumor cell growth. This dual-action mechanism is particularly valuable in treating cancers that have progressed following treatment with other HER2-targeted agents.

Key Therapeutic Uses (Combination Therapy):

  • With Capecitabine: For patients whose cancer has progressed after prior therapy including an anthracycline, a taxane, and trastuzumab.

  • With Letrozole: For postmenopausal women with hormone receptor-positive and HER2-positive metastatic breast cancer.

We offer an exclusive PCD Pharma Franchise opportunity for LAPANIB 250, providing partners with monopoly rights in this specialized, high-demand segment of targeted breast cancer therapeutics.

Read More

About the Product

LAPANIB 250 Tablet (Lapatinib 250 mg) is a highly specialized, oral, targeted cancer medicine classified as a Dual Tyrosine Kinase Inhibitor (TKI). It is a critical treatment component for patients diagnosed with HER2-positive advanced or metastatic breast cancer.

Mechanism and Impact:Lapatinib works by selectively and reversibly binding to the intracellular domain of two key receptors: Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor (EGFR). By competitively blocking the signaling pathways, Lapatinib effectively halts the uncontrolled tumor cell growth. This dual-action mechanism is particularly valuable in treating cancers that have progressed following treatment with other HER2-targeted agents.

Key Therapeutic Uses (Combination Therapy):

  • With Capecitabine: For patients whose cancer has progressed after prior therapy including an anthracycline, a taxane, and trastuzumab.

  • With Letrozole: For postmenopausal women with hormone receptor-positive and HER2-positive metastatic breast cancer.

We offer an exclusive PCD Pharma Franchise opportunity for LAPANIB 250, providing partners with monopoly rights in this specialized, high-demand segment of targeted breast cancer therapeutics.

Common side effects may include headache, constipation, dry mouth, and dizziness. Rarely, serious side effects such as allergic reactions, blurred vision, or irregular heartbeat may occur.

Indicated for the prevention and treatment of nausea and vomiting caused by chemotherapy, radiotherapy, or surgery. To be used under medical guidance.

Use under the supervision of a healthcare professional. Inform your doctor about any existing heart, liver, or gastrointestinal conditions. Do not exceed the prescribed dosage.

Store below 25°C in a cool, dry place away from direct light. Keep out of reach of children. Dispose of unused medicine as per medical advice.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation

@2024 | copy rights by Cafoli